To assess HNF-1β role in restoring the intestinal barrier with HD treatment, we administered 200 μL of 5 × 1010 AAV physical particles in PBS via tail vein injection into C57BL/6 mice 1 week prior to the experiment to silence HNF-1β. This evidence concerns the gene HNF1B and Huntington disease.